Navigation Links
Scripps Research wins more than $2 million to study prostate cancer
Date:4/26/2011

JUPITER, FL, April 26, 2011 The Scripps Research Institute and Tampa's Moffitt Cancer Center have been awarded more than $2 million to study the formation and progression of prostate cancer. Of the funds awarded, approximately $1.9 million will go to Scripps Research, with the remaining $138,380 supporting Moffitt Cancer Center work.

The five-year grant from the National Institutes of Health (NIH) will fund research to advance the development of novel therapeutic strategies for prostate cancer treatment and prevention.

"This new funding will help us continue our work into the origins of prostate cancer and the role that inflammation plays in its development," said Jun-Li Luo, PhD, an assistant professor on the Florida campus of Scripps Research and principal investigator for the new study. "We are pleased that Moffitt, one of the country's leading treatment and research centers, will be our partner in this research. Gaining a better understanding of the inflammatory process should help lay the foundation for developing novel therapeutic strategies for this disease."

"This collaboration with Scripps Florida is a great opportunity to help uncover the underlying mechanisms of prostate cancer," said Shohreh Dickinson, MD, an assistant professor at Moffitt, where scientists will study and interpret pathology slides of human cells as part of the new study. "It's also a great opportunity for two Florida research centers to advance the science that, hopefully, will one day help put an end to this terrible disease."

Prostate cancerwhich, according to the American Cancer Society, will affect one in six American men in their lifetimeis the second-leading cause of death after lung cancer in American men. Prostate cancer is driven by androgen, the male sex hormone, and androgen deprivation is considered a first-line treatment of the disease once it spreads beyond the prostate gland.

Eventually, all prostate cancer becomes resistant to the treatment, and the disease grows independently of androgen. This can occur almost anytime during treatment. Currently there are no effective treatments for what is known as hormone-refractory prostate cancer.

Luo's work has long been focused on the role of inflammation in cancer and the body's innate inflammatory response, which encourages tumor growth. In earlier studies, he found that blocking one of the factors involved in inflammationthe nuclear factor-kappa B (NF-kB)dramatically impaired development of the disease. In addition, Luo has identified tumor-infiltrating B cells as another critical component of the inflammatory response that enhances androgen-independent tumor growth.

The new study will further define how B cells control the spread of hormone refractory cancer.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related medicine news :

1. New lupus drug results from Scripps Research technology
2. Scripps Research and MIT scientists discover class of potent anti-cancer compounds
3. Scripps Research study points to liver, not brain, as origin of Alzheimers plaques
4. Scripps Research compound blocks brain cell destruction in Parkinsons disease
5. Scripps Research scientists develop powerful new methodology for stabilizing proteins
6. Scripps Research scientists find measles natural nemesis
7. Scripps Research scientists awarded $2.35 million to study new obesity treatment
8. Scripps Research scientists identify first synthetic activator of 2 critical proteins
9. Scripps Clinic nurse to receive 2010 ASTRO Nurse Excellence Award
10. Scripps and Trius team up to develop new antibiotics with US Department of Defense grant
11. Scripps Research scientists solve long-standing mystery of protein quality control mechanism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 /PRNewswire/ ... health and big data solutions, today announced that its MyDario product is ... your local TV listings for when The Dr. Oz Show airs in ... The nine-time ... month. ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: